Mundipharma demonstrates innovative ways to prevent infectious diseases at APSIC Congress

February 14, 2017 - 5 minutes read
  • Biennial Congress brings together global infection control and infectious disease experts
  • Mundipharma shows its continued efforts to support research on infections
  • Hand wash simulation study further validates the role of Povidone-Iodine (PVPI) BETADINE® against tough to kill viruses
  • New app will showcase the role of digital technology in targeted hygiene strategies

Singapore 13 February, 2017: During the 8th International congress of the Asia Pacific Society of Infection Control (APSIC) in Bangkok, Thailand, leading healthcare company, Mundipharma, will be sponsoring medical educational programs with an international panel to discuss solutions and initiatives to tackle challenges in antimicrobial resistance as well as the importance of proper hygiene practices.

At the Congress, Mundipharma will share evidence about how BETADINE® medicines that contain PVPI can be used as a virucide against seasonal infections such as flu, as well as help to prevent infectious disease outbreaks such as MERS, SARS, Ebola, HFMD (Hand Foot and Mouth Disease) and Norovirus in both public and hospital settings. The positive results generated by a leading virologist on PVPI’s role against tough to kill viruses and its role in public health will also be presented.

In addition, Mundipharma will showcase a digital app as part of its support of the objectives outlined in the WHO’s Global Action Plan on Antimicrobial Resistance to improve hygiene measures, reduce infection and limit the use of antibiotics.

“Recent global viral outbreaks and the challenges presented by nosocomial infections demonstrate the critical importance of infection control in the race to limit the spread of infections,” said Raman Singh, President Mundipharma Asia Pacific, Latin America the Middle East & Africa.

“The live demonstration will include an exchange with infection control experts on how digital solutions can drive better hygiene practices to reduce infections and limit the use of antibiotics. In today’s highly digitalized world, the app will be a game changer as it will be able to be shared, downloaded and used faster than diseases can spread.”

“Mundipharma brings to the congress a team of independent experts with deep experience in infection control. They will discuss the appropriate use of antiseptics, antibiotics and hygiene interventions that limit the spread of resistant microorganisms and reduce antimicrobial misuse and overuse, as well as a perspective on the targeted hygiene concept – aimed at implementing a risk-based approach to hygiene.

 

ENDS.

 

ABOUT MUNDIPHARMA
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

ABOUT APSIC
The Asia Pacific Society of Infection Control (APSIC) was established in 1998 and is a multi-national, voluntary, organization dedicated to the advancement of infection control practice to reduce hospital associated infections, monitor and control emerging and re-emerging infectious diseases and improved patient outcomes.

APSIC brings together multidisciplinary infection control professionals in the region to share their knowledge, experience, skills, and quality improvement and research findings by facilitating the exchange of information through training courses, seminars, congresses and conferences in the Asia Pacific region.

®: BETADINE is a registered trademark of Mundipharma

Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.

 

For further information please contact:
Stephenie Vasko
Chief Communications Officer & Head, Digital Strategy –
Asia Pacific, Latin America the Middle East & Africa
+65-6303-9732 | stephenie.vasko@mundipharma.com.sg